Tenderwize
Zurück zur Suche

Open house discount agreements for active substance Tolvaptan, ATC G04BX21

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 29, 2028 · 552 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Tolvaptan, ATC G04BX21

30/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

30 / 100

Komplexität

20 / 100

Risikofaktoren

The buyer reserves the right to replace open house agreements with exclusive contracts during the term, which automatic...

No estimated value or volume is provided. Revenue potential is unclear, and the agreements may yield minimal discount-b...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Conclusion of non-exclusive discount agreements for pharmaceuticals with active substance Tolvaptan (ATC G04BX21)
  • Open house model: all eligible pharmaceutical companies can join on uniform terms
Vollständige Zusammenfassung anzeigen

Open house non-exclusive discount agreements for the active substance Tolvaptan (ATC G04BX21) by AOK Rheinland-Pfalz/Saarland. All pharmaceutical companies can join on uniform terms from May 2026 to April 2028. No estimated value provided. The procedure is not a formal public procurement but published for transparency.

Risiken

The buyer reserves the right to replace open house agreements with exclusive contracts during the term, which automatic...

No estimated value or volume is provided. Revenue potential is unclear, and the agreements may yield minimal discount-b...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Products must be authorized and marketable in Germany (listed in Lauer-Taxe or AMIce database)

Eligibility

  • Only pharmaceutical companies are eligible to participate

Administrative

  • Submission of signed contract documents either in paper (two copies, plus scan) or electronically with qualified electronic signature

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

No award criteria; all eligible pharmaceutical companies are accepted under uniform conditions.

Auftraggeber

Lose (1)

LOT-0001

Open house discount agreements for active substance Tolvaptan, ATC G04BX21

Non-exclusive rebate contracts for Tolvaptan products. Open to all pharmaceutical companies with authorized and marketable products in Germany. Uniform conditions, no negotiation. Maximum 24-month term, earliest start 01.05.2026. Buyer may replace with exclusive contracts during the term, terminating open house agreements automatically.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Apr 2026 - Apr 2028

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria; all eligible pharmaceutical companies are accepted under uniform conditions.

Frist

Deadline Feb 29, 2028

Vergabedetails

Veröffentlichungsdatum
15 Mar 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
178098-2026

Dokumente (1)

Ähnliche Ausschreibungen